In this article, we will look at the 11 Best Australian Stocks to Buy According to Analysts.
Australia’s Economic Outlook for 2025
The tariffs announced by the United States have challenged the economic and market outlooks around the globe. On April 7, BlackRock released its quarterly review and outlook for the Australian economy. The report highlighted that the Reserve Bank of Australia (RBA) cut the cash rates to 4.10% after a 0.25% decrease during the first quarter of 2025. This was in line with the expectations, which pointed towards a more dovish approach in the upcoming quarters as well.
Market expectations before the tariffs were announced were that the RBA would reduce the rate by 0.25% in July 2025 and by another 0.25% in November. However, with tariffs in place and market uncertainty, the rate cuts are expected to be in effect sooner than expected. The report anticipates that the RBA will likely cut rates in May this year, followed by at least two more cuts in 2025. The bank decided to keep the rates unchanged during the latest April meeting, as per the report, this was due to the high level of uncertainty that remains around inflation. The data regarding inflation suggests that the underlying inflation continues to ease in line with the forecasts. During the April meeting, the RBA emphasized the importance of keeping the inflation around the midpoint of 2.5%, however, the current forecasts suggest that it will remain over 2.7%, thereby indicating potential rate cuts by the RBA.
In terms of GDP, the Real GDP came in above RBA forecasts during Q4 2024 after growing 1.3% year-over-year. The report attributed this growth to a recovery in household consumption and a strong public demand. Moreover, while the demand side remains healthy, the supply side has been constrained due to a weak labor productivity, indicated by unit labor cost rising 1.7% quarter-over-quarter.
The report also discussed the impact of tariffs on the Australian Economy. In 2024, Australia exported goods worth $24 billion to the United States. This was less than 1% of Australia’s GDP. If we take 2024 figures as a benchmark, this suggests that a 10% tariff on Australia can negatively impact the GDP by $2.4 billion. The report highlights that while the direct impact of tariffs might not be damaging for the economy, however, the indirect impact in terms of the global growth prospects and higher inflation can be risky. On the positive side, the RBA anticipates that tariffs on China can be helpful as it is likely to direct its exports to other markets, including Australia, resulting in local disinflation.
With that, let’s take a look at the 11 best Australian stocks to buy according to analysts.
A trader in a financial institution using fundamentals analysis to select stocks for a portfolio.
Our Methodology
To compile the list of 11 best Australian stocks to buy according to analysts, we used the Finviz stock screener and CNN. Using the screener, we aggregated a list of Australian stocks with an upside potential of more than 30%. We cross-checked each stock’s upside potential using CNN and ranked the stocks in ascending order. We have also added the hedge fund sentiment around each stock sourced from Insider Monkey’s Q4 2024 database. Please note that the data was collected on May 14, 2025.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
11 Best Australian Stocks to Buy According to Analysts
11. Telix Pharmaceuticals Limited (NASDAQ:TLX)
Number of Hedge Fund Holders: N/A
Analyst Upside Potential: 31.95%
Telix Pharmaceuticals Limited (NASDAQ:TLX) is an international biopharmaceutical company based in Australia. It engages in the development and commercialization of diagnostic radiopharmaceuticals, as well as associated medical technologies. The company mainly focuses on Therapeutics, Precision Medicines, and Telix Manufacturing Solutions.
Telix Pharmaceuticals Limited (NASDAQ:TLX) released its fiscal first quarter results on April 22. Management noted that now there are two FDA-approved PSMA-PET imaging agents by the company, including Illuccix and Gozellix. This strengthens the company’s strategic position and market capitalization. Moreover, the FDA approval and upcoming US launch of Gozellik are expected to further expand its footprint in prostate cancer diagnostics. Telix Pharmaceuticals Limited (NASDAQ:TLX) generated $186 million in revenue for the quarter, representing a 62% increase year-over-year. The growth was mainly driven by a 35% increase in global sales of Illuccix.
Looking ahead, management has reaffirmed its full-year revenue guidance of $770 million to $800 million. Analysts anticipate significant upside for the stock, making it one of the best Australian stocks to buy, according to analysts.
10. ioneer Ltd (NASDAQ:IONR)
Number of Hedge Fund Holders: N/A
Analyst Upside Potential: 76.95%
ioneer Ltd (NASDAQ:IONR) is an Australian-based mining company that engages in the production of lithium and boron. One of its flagship projects is the Rhyolite Ridge Lithium-Boron Project located in Esmeralda County, USA. This project contains two lithium-boron deposits.
On May 2, Matthew Hope from Ord Minnett maintained a Buy rating on the stock with a price target of A$0.30. ioneer Ltd (NASDAQ:IONR) released its quarterly activities report on April 15. The company highlighted that it secured a $996 million loan from the US Department of Energy under the Advanced Technology Vehicles Manufacturing program. Management noted that this funding supports the development of an on-site processing facility at its Rhyolite Ridge Lithium-Boron Project in Nevada.
Moreover, ioneer Ltd (NASDAQ:IONR) in March 2025 announced an increase in Mineral Resource Estimates for its project. The upgraded estimates indicate a 45% increase, now projecting 510 million tonnes of mineral resources containing 3.97 million tonnes of lithium carbonate equivalent and 14.66 million tonnes of boric acid equivalent. Management noted that these resources are all located within the fully permitted project area approved by the US government in October 2024 and supported by the $996 million DOE loan. Analysts expect significant upside for ioneer Ltd (NASDAQ:IONR) considering the improved projection regarding resources. The company ranks as one of the best Australian stocks to buy according to analysts.
9. Nova Minerals Limited (NASDAQ:NVA)
Number of Hedge Fund Holders: 1
Analyst Upside Potential: 99.81%
Nova Minerals Limited (NASDAQ:NVA) is a mineral exploration company based in Australia. It engages in the exploration and development of gold, antimony, and other critical materials. Its flagship project is the Estelle Project, a 514 square kilometer property located in Alaska.
The company released its minerals quarterly activity report on April 11, highlighting significant discoveries in its 2024 surface exploration program. For instance, the rock samples at the Wombat prospect returned exceptionally high gold grades, with values up to 360 grams per tonne. Moreover, at the RPM Regional area, more high-grade gold was identified with rock samples up to 56.3 g/t Au and soil samples up to 4.8 g/t Au.
Financially speaking, at the end of March 31, 2025, Nova Minerals Limited (NASDAQ:NVA) had A$13.076 million in cash and no debt. Looking ahead, the company is progressing towards pre-feasibility studies, including metallurgical and environmental test work, aiming to advance the Estelle Project toward development and production. It is one of the best Australian stocks to buy according to analysts.
8. Mesoblast Limited (NASDAQ:MESO)
Number of Hedge Fund Holders: 2
Analyst Upside Potential: 101.51%
Mesoblast Limited (NASDAQ:MESO) is another Australian biotechnology company that develops and commercializes allogeneic cellular medicines. These medicines are designed to treat severe inflammatory and immune-mediated conditions. The company uses its proprietary mesenchymal lineage cell therapy technology platform to develop a broad portfolio of late-stage product candidates.
On May 1, Bell Potter analyst John Hester maintained a Buy rating on the stock with a price target of A$3.40. The company recently underwent significant strategic and financial developments. The company got its key product, Ryoncil, approved by the FDA. The product has become the first mesenchymal stromal cell therapy approved by the US FDA to treat steroid-refractory acute graft versus host disease in children. Mesoblast Limited (NASDAQ:MESO) is leveraging its strong cash position to expand Ryoncil indications to other serious pediatric inflammatory conditions. Management noted that Ryoncil will be available for use in steroid-refractory acute GVHD in the United States this quarter, and studies will be initiated for pediatric and adult label extension indications. Mesoblast Limited (NASDAQ:MESO) is one of the best Australian stocks to buy according to analysts.
7. Tamboran Resources Corporation (NYSE:TBN)
Number of Hedge Fund Holders: 4
Analyst Upside Potential: 102.27%
Tamboran Resources Corporation (NYSE:TBN) is a natural gas company based in Australia. It focuses on developing low-carbon-dioxide unconventional reserves at the Beetaloo Sub-basin within the Greater McArthur Basin. The company holds approximately 1.9 million to 2 million net prospective acres in the Beetaloo Basin and operates several exploration permits.
The company reported significant strategic developments during the fiscal second quarter of 2025. It announced the successful drilling of SS-3H well, which was drilled, cased, and cemented to a total measured depth of 21,169 feet with a 5.5-inch casing. Management noted that it is the first well in the Beetaloo Basin to have a usable 10,000-foot horizontal section below 8,000 feet.
Moreover, Tamboran Resources Corporation (NYSE:TBN) entered into a binding agreement with APA Group to build and operate the 12-inch Sturt Plateau Pipeline for the proposed Shenandoah South Pilot Project. Management noted that it is also considering a Data Center opportunity as part of its expanded Phase 1 development, leveraging existing fiber optic networks adjacent to its operated assets in the Beetaloo Basin. It is one of the best Australian stocks to buy according to analysts.
6. NOVONIX Limited (NASDAQ:NVX)
Number of Hedge Fund Holders: 1
Analyst Upside Potential: 133.69%
NOVONIX Limited (NASDAQ:NVX) is a battery material and technology company based in Australia. It serves the electric vehicle and energy storage markets. The company operates through three main segments: Battery Material, Battery Technology, and Graphite Exploration.
The company released its quarterly activities report on April 30. NOVONIX Limited (NASDAQ:NVX) has been advancing its synthetic graphite anode production at its Riverside facility. Management is targeting an initial capacity of 3,000 tonnes per annum to fulfill its agreements with partners such as Panasonic, Stellantis, and PowerCo. The company also secured an exclusive license with Harper International for proprietary graphitization furnace technology, which is expected to optimize manufacturing efficiency and cost.
NOVONIX Limited (NASDAQ:NVX) also highlighted that it has secured approval from the local government to set up a second mass production plant to further boost its manufacturing capacity. Analysts are expecting significant upside for the company, making it one of the best Australian stocks to buy, according to analysts.
5. IREN Limited (NASDAQ:IREN)
Number of Hedge Fund Holders: 44
Analyst Upside Potential: 146.31%
IREN Limited (NASDAQ:IREN) is a technology company that operates data centers powered by renewable energy. Its facilities are optimized for Bitcoin mining, artificial intelligence, cloud services, and other high-power computing tasks. The company is headquartered in Australia and operates multiple data center mining facilities located in Canal Flats, Mackenzie, and Prince George’s in Canada.
On May 6, Compass Point analyst Joe Flynn maintained a Buy rating on the stock with a price target of $15. The bullish sentiment is backed by the company’s significant progress in expanding its Bitcoin mining capacity, which reached 40 exahashes per second as per the April 2025 update. Management noted that this growth is driven by commissioning additional mining hardware, particularly within the company’s Childress Phase 4 data centers, which achieved an efficiency of 15 joules per terahash.
Alongside mining expansion, IREN Limited’s (NASDAQ:IREN) AI Cloud Services revenue continues to grow, supported by the development of its Horizon 1 AI Data Center. During April 2025, the AI Cloud Services revenue reached $2 million, up from $1.6 million last month. IREN Limited (NASDAQ:IREN) is one of the best Australian stocks to buy according to analysts.
4. Immuron Limited (NASDAQ:IMRN)
Number of Hedge Fund Holders: N/A
Analyst Upside Potential: 161.78%
Immuron Limited (NASDAQ:IMRN) is a biopharmaceutical company that specializes in the development and commercialization of polyclonal antibodies for treating infectious diseases. It operates through two main business segments, including the Research and Development and Hyperimmune Products segments.
The company released its March quarter results for 2025. During the quarter, Immuron Limited (NASDAQ:IMRN) surpassed AUD$5 million in a fiscal year to reach AUD$5.3 million year-to-date as of March 2025. This represented a 46% increase year-over-year, marking the highest sales in the company’s history.
Moreover, on March 5, Immuron Limited (NASDAQ:IMRN) reported that it has entered into a definitive agreement to launch ProIBS in Australia and New Zealand. ProIBS is a certified medical device designed to relieve symptoms associated with Irritable Bowel Syndrome. The CEO of the company emphasized that the ProIBS complements the company’s premium efficacy product range and provides pharmacists with a scientifically backed, physician-recommended option to improve patient outcomes. The company ranks as one of the best Australian stocks to buy according to analysts.
3. Alterity Therapeutics Limited (NASDAQ:ATHE)
Number of Hedge Fund Holders: 1
Analyst Upside Potential: 189.16%
Alterity Therapeutics Limited (NASDAQ:ATHE) is a clinical-stage biopharmaceutical company engaged in developing disease-modifying treatments for neurodegenerative diseases. Its lead candidate is ATH434, which is an oral small molecule designed to inhibit the aggregation of pathological proteins involved in neurodegeneration. ATH434 is being developed primarily to treat Parkinson’s disease and related Parkinsonian disorders.
On April 29, Alterity Therapeutics Limited (NASDAQ:ATHE) announced positive results from its ATH434-201 Phase 2 clinical trial. The placebo-controlled tests showed that ATH434 significantly slowed the clinical progression of Multiple System Atrophy. The 50 mg dosage showed a 48% reduction in disease progression at 52 weeks, and the 75 mg dose showed a 29% reduction at the same time point.
Moreover, on May 5, the company announced that it had been granted fast-track FDA approval for ATH434 to Treat Multiple System Atrophy. The fast track offers several benefits, including eligibility for accelerated approval and priority review if criteria are met, rolling review of the New Drug Application, and more frequent communication with the FDA. Alterity Therapeutics Limited (NASDAQ:ATHE) is one of the best Australian stocks to buy according to analysts.
2. Immutep Limited (NASDAQ:IMMP)
Number of Hedge Fund Holders: 2
Analyst Upside Potential: 260.08%
Immutep Limited (NASDAQ:IMMP) is a clinical-stage biopharmaceutical company that is engaged in developing immunotherapies to treat cancer and autoimmune diseases by targeting Lymphocyte Activation Gene-3 (LAG-3).
On May 7, Jason McCarthy, an analyst from Maxim Group, maintained a Buy rating on the stock with a price target of $12. The analyst highlighted the positive results of the Phase 2b TACTI-003 study. The study tested the combination of Eftilagimod alpha and Keytruda in first-line treatment for cancer patients. The results showed a promising overall median survival data of 17.6 months. This was significantly better than historical benchmarks with other treatments like cetuximab with chemotherapy or Keytruda with chemotherapy.
The analyst also noted that the safety profile of the combination is better than chemotherapy. Immutep Limited (NASDAQ:IMMP) has started discussions with the FDA to explore regulatory pathways for accelerating the approval. The company ranks as one of the best Australian stocks to buy according to analysts.
1. Radiopharm Theranostics Limited (NASDAQ:RADX)
Number of Hedge Fund Holders: 2
Analyst Upside Potential: 278.79%
Radiopharm Theranostics Limited (NASDAQ:RADX) is a clinical-stage biopharmaceutical company that specializes in radiopharmaceuticals for cancer treatment. It is preparing a diverse pipeline of highly differentiated molecules, including peptides, small molecules, and monoclonal antibodies.
On April 29, Radiopharm Theranostics Limited (NASDAQ:RADX) released its quarterly activity report, highlighting that it raised $5 million through a private placement of 133 million shares to Lantheus Holdings Inc. at A$0.060 per share. This investment increased Lantheus’s stake in Radiopharm to 12.16%, making it the largest shareholder in the company. Moreover, the company is making progress in its pipeline. The recent clinical data highlighted Radiopharm Theranostics Limited (NASDAQ:RADX) imaging agent RAD 101, which successfully detects brain metastases with high sensitivity and specificity using a novel PET/mpMRI imaging approach.
Additionally, the preclinical data for RAD202 also showed strong tumor uptake and favorable biodistribution, supporting its diagnostic and therapeutic potential in HER2-positive cancers. The recent fundraising and clinical developments have placed Radiopharm Theranostics Limited (NASDAQ:RADX) among one of the best Australian stocks to buy according to analysts.
While we acknowledge the potential of WRD to grow, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than WRD but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure. None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and investors. Please subscribe to our daily free newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
